IP Library › Granted Patent US 10,351,561
Granted Patent B2
US 10,351,561 · App. 15/849,798 · Granted Jul 16, 2019

Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors

Inventors: Jan Kehler (Valby, DK); Lars Kyhn Rasmussen (Valby, DK); Morten Langgard (Valby, DK); Mikkel Jessing (Valby, DK); Paulo Jorge Vieira Vital (Valby, DK); Karsten Juhl (Valby, DK); Mauro Marigo (Valby, DK)
Assignee: H. Lundbeck A/S
C07D471/04A61P25/00A61P25/16A61P25/18A61P25/28C07D487/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,351,561
App. No.
15/849,798
Granted
Jul 16, 2019
Kind
B2
Abstract

The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

Claims (129)

1. A compound of formula (I)

wherein

Y 1 =N—R 1 , Y 2 =C and Y 3 =C, or

Y 1 =C—R 1 , Y 2 =N and Y 3 =C;

Z 1 is selected from NH, CH 2 , O and S;

Z 2 is selected from NH, CH 2 , O and S;

with the proviso that at least one of Z 1 and Z 2 is CH 2 ;

R 1 is selected from the group consisting of hydrogen, linear or branched C 1-4 alkyl and saturated monocyclic C 3-4 cycloalkyl, wherein said linear or branched C 1-4 alkyl and saturated monocyclic C 3-4 cycloalkyl can be optionally substituted with one or more halogen;

R 2 is selected from the group consisting of linear or branched C 1-6 alkyl, saturated monocyclic C 3-6 cycloalkyl, oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, all of which can optionally be substituted with one or more halogen;

R 3 is a 5- or 6-membered heteroaryl, which can optionally be substituted with one or more substituents selected from linear or branched C 1-4 alkyl, linear or branched C 1-4 alkoxy and halogen, wherein said linear or branched C 1-4 alkyl and linear or branched C 1-4 alkoxy can be optionally substituted with one or more halogen, or

R 3 is a 9-membered bicyclic heteroaryl, which can optionally be substituted with one or more substituents selected from linear or branched C 1-4 alkyl, linear or branched C 1-4 alkoxy and halogen, wherein said linear or branched C 1-4 alkyl and linear or branched C 1-4 alkoxy can be optionally substituted with one or more halogen;

R 4 is a 5- or 6-membered heteroaryl, which can optionally be substituted with one or more substituents selected from linear or branched C 1-4 alkyl, linear or branched C 1-4 alkoxy and halogen, wherein said linear or branched C 1-4 alkyl and linear or branched C 1-4 alkoxy can be optionally substituted with one or more halogen, or

R 4 is a phenyl, which can optionally be substituted with one or more substituents selected from linear or branched C 1-4 alkyl, linear or branched C 1-4 alkoxy and halogen, wherein said linear or branched C 1-4 alkyl and linear or branched C 1-4 alkoxy can be optionally substituted with one or more halogen, or

R 4 is a pyridinone, which can optionally be substituted with one or more substituents selected from linear or branched C 1-4 alkyl, linear or branched C 1-4 alkoxy and halogen, wherein said linear or branched C 1-4 alkyl and linear or branched C 1-4 alkoxy can be optionally substituted with one or more halogen; or

R 4 is a 9-membered bicyclic heteroaryl, which can optionally be substituted with one or more substituents selected from linear or branched C 1-4 alkyl, linear or branched C 1-4 alkoxy and halogen, wherein said linear or branched C 1-4 alkyl and linear or branched C 1-4 alkoxy can be optionally substituted with one or more halogen;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 of formula (Ia)

wherein Z 1 , Z 2 , R 1 , R 2 , R 3 and R 4 are as defined in claim 1 ;

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 of formula (Ib)

wherein Z 1 , Z 2 , R 1 , R 2 , R 3 and R 4 are as defined in claim 1 ;

or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 , wherein Z 1 is NH.

5. The compound according to claim 1 , wherein Z 2 is CH 2 .

6. The compound according to claim 1 , wherein Z 1 is NH and Z 2 is CH 2 .

7. The compound according to claim 1 , wherein R 1 is a linear or branched C 1-4 alkyl.

8. The compound according to claim 1 , wherein R 2 is linear or branched C 1-6 alkyl.

9. The compound according to claim 1 , wherein

R 3 is a 5-membered heteroaryl selected from pyrazolyl, imidazolyl, oxazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiazolyl and thiophenyl, all of which can optionally be substituted with a methyl; or

R 3 is a 6-membered heteroaryl, which can optionally be substituted with a substituent selected from methyl, trifluoromethyl or a linear or branched C 1-4 alkoxy; wherein said 6-membered heteroaryl is selected from pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl; or

R 3 is a 9-membered bicyclic heteroaryl, which is optionally substituted with one or more methyl.

10. The compound according to claim 1 , wherein

R 4 is a 5-membered heteroaryl selected from pyrazolyl, imidazolyl, oxazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiazolyl and thiophenyl wherein said 5-membered heteroaryl can be optionally substituted with a methyl; or

R 4 is a 6-membered heteroaryl, which can optionally be substituted with a linear or branched C 1-4 alkoxy; wherein said 6-membered heteroaryl is selected from pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl; or

R 4 is a phenyl, which can optionally be substituted with one or more methyl; or

R 4 is a pyridinone, which can optionally be substituted with one or more methyl; or

R 4 is a 9-membered bicyclic heteroaryl, which can optionally be substituted with one or more methyl.

11. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

2) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(2-methyloxazol-4-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

3) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(1H-pyrazol-3-ylmethyl)pyrazolo[3,4-b]pyridin-4-amine;

4) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

5) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

6) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-(5-methyl-1H-pyrazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

7) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-N-[(2-ethoxy-4-pyridyl)methyl]-1-methyl pyrazolo[3,4-b]pyridin-4-amine;

8) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(1-methylimidazol-4-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

9) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(2-methyloxazol-4-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

10) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-(1H-pyrazol-3-ylmethyl)imidazo[1,5-b]pyrazin-4-amine;

11) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

12) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

13) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(5-methyl-1H-pyrazol-3-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

14) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-N-[(5-methoxy-3-pyridyl)methyl]-7-methyl-imidazo[1,5-b]pyridazin-4-amine;

15) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-N-[(2-methoxy-4-pyridyl)methyl]-7-methyl-imidazo[1,5-b]pyridazin-4-amine;

16) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(2-methyloxazol-5-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

17) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(2-methylthiazol-5-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

18) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-(1H-pyrazol-4-ylmethyl)imidazo[1,5-b]pyridazin-4-amine;

19) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(1-methylpyrazol-4-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

20) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(2-methyltetrazol-5-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

21) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(1-methylpyrazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

22) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(1-methylpyrazol-4-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

23) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(2-methyltetrazol-5-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

24) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(1-methylpyrazol-3-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

25) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-N-[(5-methoxy-3-pyridyl)methyl]-1-methyl-pyrazolo[3,4-b]pyridin-4-amine;

26) 6-(2-ethoxypyridin-3-yl)-3-isopropyl-1-methyl-N-((2-methyl-2H-1,2,3-triazol-4-yl)methyl) 1H-pyrazolo[3,4-b]pyridin-4-amine;

27) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(2-methyloxazol-5-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

28) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(2-methylthiazol-5-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

29) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(1-methyltriazol-4-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

30) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-(1H-pyrazol-4-ylmethyl)pyrazolo[3,4-b]pyridin-4-amine;

31) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1l-methyl-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

32) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

33) 3-isopropyl-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]-6-(2-propoxy-3-pyridyl)pyrazolo[3,4-b]pyridin-4-amine;

34) 3-isopropyl-1-methyl-N-[(1-methylimidazol-4-yl)methyl]-6-(2-propoxy-3-pyridyl)pyrazolo[3,4-b]pyridin-4-amine;

35) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(4-methylpyrimidin-2-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

36) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-(pyrimidin-2-ylmethyl)pyrazolo[3,4-b]pyridin-4-amine;

37) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-N-[(6-methoxy-3-pyridyl)methyl]-1-methyl-pyrazolo[3,4-b]pyridin-4-amine;

38) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[[2-(trifluoromethyl)-pyridyl]methyl]pyrazolo[3,4-b]pyridin-4-amine;

39) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-N-[(4-methoxy-2-pyridyl)methyl]-1-methyl-pyrazolo[3,4-b]pyridin-4-amine;

40) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-(2-pyridylmethyl)pyrazolo[3,4-b]pyridin-4-amine;

41) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-N-[(6-methoxy-2-pyridyl)methyl]-1-methyl-pyrazolo[3,4-b]pyridin-4-amine;

42) 6-(2-ethoxy-3-pyridyl)-3-isopropyl-1-methyl-N-[(6-methyl-2-pyridyl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

43) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-(1,2,4-oxadiazol-3-ylmethyl)imidazo[1,5-b]pyridazin-4-amine;

44) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(2-methyltriazol-4-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

45) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(5-methyl-1,3,4-oxadiazol-2-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

46) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

47) (−)-2-(2-ethoxy-3-pyridyl)-7-methyl-N-[(1-methylpyrazol-4-yl)methyl]-5-[1-methylpropyl]imidazo[1,5-b]pyridazin-4-amine;

48) (+)-2-(2-ethoxy-3-pyridyl)-7-methyl-N-[(1-methylpyrazol-4-yl)methyl]-5-[1-methylpropyl]imidazo[1,5-b]pyridazin-4-amine;

49) (−)-2-(2-ethoxy-3-pyridyl)-7-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]-5-[1-methylpropyl]imidazo[1,5-b]pyridazin-4-amine;

50) (+)-2-(2-ethoxy-3-pyridyl)-7-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]-5-[1-methylpropyl]imidazo[1,5-b]pyridazin-4-amine;

51) (+)-2-(2-ethoxy-3-pyridyl)-7-methyl-N-(1H-pyrazol-3-ylmethyl)-5-[1-methylpropyl]imidazo[1,5-b]pyridazin-4-amine;

52) (−)-2-(2-ethoxy-3-pyridyl)-7-methyl-N-(1H-pyrazol-3-ylmethyl)-5-[1-methylpropyl]imidazo[1,5-b]pyridazin-4-amine;

53) (+)-2-(2-ethoxy-3-pyridyl)-N-[(2-methoxy-4-pyridyl)methyl]-7-methyl-5-[1-methylpropyl]imidazo[1,5-b]pyridazin-4-amine;

54) (−)-2-(2-ethoxy-3-pyridyl)-N-[(2-methoxy-4-pyridyl)methyl]-7-methyl-5-[1-methylpropyl]imidazo[1,5-b]pyridazin-4-amine;

55) 3-isopropyl-6-(2-methoxy-3-pyridyl)-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

56) 3-(3-isopropyl-1-methyl-4-(((1-methyl-1H-1,2,4-triazol-3-yl)methyl)amino)-1H-pyrazolo[3,4-b]pyridin-6-yl)-1-methylpyridin-2(1H)-one;

57) 3-isopropyl-6-(3-methoxypyrazin-2-yl)-1-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1H-pyrazolo[3,4-b]pyridin-4-amine;

58) 3-isopropyl-1-methyl-6-(2-methyl-3-thienyl)-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

59) 3-isopropyl-1-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-6-(4-methyloxazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine;

60) 3-isopropyl-1-methyl-6-(4-methylthiazol-2-yl)-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

61) 3-isopropyl-1-methyl-N-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-6-(4-methylthiazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine;

62) 3-isopropyl-1-methyl-6-(5-methylthiazol-2-yl)-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

63) 3-isopropyl-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]phenyl-pyrazolo[3,4-b]pyridin-4-amine;

64) 3-isopropyl-6-(4-methoxypyrimidin-5-yl)-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

65) 3-isopropyl-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]-6-(2-thienyl)pyrazolo[3,4-b]pyridin-4-amine;

66) 6-(3-ethoxypyridazin-4-yl)-3-isopropyl-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

67) 3-isopropyl-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]-6-(3-propoxypyridazin-4-yl)pyrazolo[3,4-b]pyridin-4-amine;

68) 6-(3-ethoxy-4-pyridyl)-3-isopropyl-1-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]pyrazolo[3,4-b]pyridin-4-amine;

69) 2-(3-ethoxypyridazin-4-yl)-5-isopropyl-7-methyl-N-[(1-methylpyrazol-4-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

70) 2-(3-ethoxy-4-pyridyl)-5-isopropyl-7-methyl-N-[(1-methylpyrazol-4-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

71) 5-isopropyl-7-methyl-N-[(1-methylpyrazol-4-yl)methyl]-2-(2-propoxy-3-pyridyl)imidazo[1,5-b]pyridazin-4-amine;

72) 5-isopropyl-7-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]-2-(2-propoxy-3-pyridyl)imidazo[1,5-b]pyridazin-4-amine;

73) 2-(2-ethoxy-3-pyridyl)-N-[(2-fluoro-3-pyridyl)methyl]-5-isopropyl-7-methyl-imidazo[1,5-b]pyridazin-4-amine;

74) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-(2-pyridylmethyl)imidazo[1,5-b]pyridazin-4-amine;

75) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-(pyrimidin-2-ylmethyl)imidazo[1,5-b]pyridazin-4-amine;

76) 2-(2-ethoxy-3-pyridyl)-N-[(5-fluoropyrimidin-2-yl)methyl]-5-isopropyl-7-methyl-imidazo[1,5-b]pyridazin-4-amine;

77) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-N-[(2-methoxy-3-pyridyl)methyl]-7-methyl-imidazo[1,5-b]pyridazin-4-amine;

78) 2-(2-ethoxy-3-pyridyl)-N-(imidazo[1,5-a]pyridin-5-ylmethyl)-5-isopropyl-7-methyl-imidazo[1,5-b]pyridazin-4-amine;

79) 2-(2-ethoxy-3-pyridyl)-N-(imidazo[1,2-a]pyridin-5-ylmethyl)-5-isopropyl-7-methyl-imidazo[1,5-b]pyridazin-4-amine;

80) 2-(2-ethoxy-3-pyridyl)-5-isopropyl-7-methyl-N-[[2-(trifluoromethyl)-3-pyridyl]methyl]imidazo[1,5-b]pyridazin-4-amine;

81) 2-(1,3-benzoxazol-7-yl)-5-isopropyl-7-methyl-N-[(1-methyl-1,2,4-triazol-3-yl)methyl]imidazo[1,5-b]pyridazin-4-amine;

and pharmaceutically acceptable salts thereof.

12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents and/or excipients.

13. The compound according to claim 2 , wherein Z 1 is NH.

14. The compound according to claim 2 , wherein Z 2 is CH 2 .

15. The compound according to claim 2 , wherein R 1 is a linear or branched C 1-4 alkyl.

16. The compound according to claim 2 , wherein R 2 is a linear or branched C 1-4 alkyl.

17. The compound according to claim 3 , wherein Z 1 is NH.

18. The compound according to claim 3 , wherein Z 2 is CH 2 .

19. The compound according to claim 3 , wherein R 1 is a linear or branched C 1-4 alkyl.

20. The compound according to claim 3 , wherein R 2 is a linear or branched C 1-4 alkyl.

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 11 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents and/or excipients.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2018
From: KEHLER, JAN; RASMUSSEN, LARS KYHN; LANGGARD, MORTEN; JESSING, MIKKEL; VIERA VITAL, PAULO JORGE; JUHL, KARSTEN; MARIGO, MAURO
To: H. LUNDBECK A/S
Reel/Frame 045782/0360 →
Priority Claims (2)
DK 201600784 · Dec 22, 2016 · national
DK 201700404 · Jul 6, 2017 · national
Continuity (1)
Related Publication 20180179200A1 · Jun 28, 2018
Cited By (1)
US 12,643,910